Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 2020

View Archived Issues

Pfizer studies PF-06939926 in phase III for DMD

Pfizer conducts phase I study of PF-07248144 in advanced or metastatic solid tumors

Psychedelic analogue has therapeutic potential

Discovery and preclinical evaluation of a new sGC stimulator for hypertension treatment

ONK Therapeutics signs option license agreements to strengthen NK cell therapy pipeline

Phase II data on AB-023 support use in prevention of device-associated thrombosis

Chordia Therapeutics reports preclinical data for MALT1 inhibitor

Vasomune initiates first-in-human study of AV-001 as potential therapy for COVID-19 and ARDS

Phase I/II data shows therapeutic activity of OTO-413 across multiple speech-in-noise hearing tests

Benlysta approved as the first therapy for adult patients with active lupus nephritis in the U.S.

HSF1 inhibition directly targets treatment-resistant prostate cancer

Results from first-in-human trial of BCMA-targeted ADC MEDI-2228 presented

VioGen Biosciences patents new PIKfyve inhibitors

Agios Pharmaceuticals synthesizes new MAT2A inhibitors

Angex Pharmaceutical presents new PRMT5 inhibitors

Ideaya Biosciences discloses POLH inhibitors

STP-938, a novel CTPS1 inhibitor with activity in hematological malignancies

New hMPV-derived vaccines presented by Valneva

Phase II trials of ALX-629 begin in COVID-19, atopic asthma and psoriasis

EDP-1503 plus pembrolizumab safe and well-tolerated in TNBC patients

First-in-human data presented for AB-928 with or without IPI-549 in patients with cancer

Albireo starts phase III trial of odevixibat in Alagille syndrome

Shionogi initiates phase I/II study in Japan with COVID-19 vaccine candidate

FDA clears IND for AlloVir's ALVR-106 to treat severe respiratory viral infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...